# A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.

> **NCT03772223** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 91 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Treatment A (Budesonide/Albuterol Sulfate metered dose inhaler)
- **DRUG:** Treatment B (Budesonide metered dose inhaler)
- **DRUG:** Treatment C (Albuterol Sulfate metered dose inhaler)

## Key facts

- **NCT ID:** NCT03772223
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-21
- **Primary completion:** 2019-05-10
- **Final completion:** 2019-05-10
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2019-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03772223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03772223, "A Study to Compare the Pharmacokinetics of Budesonide and Albuterol Delivered by PT027 Compared With PT007 and PT008 Administered Separately.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT03772223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*